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. The particular importance of mi RNAs within the field of urology has been reflected in the rising number of annual publications on this topic indexed in the PubMed database, which has increased from 132 in 2010 to an estimated 400 in 2016 (FIG. 1) . During this period, a considerable increase in the number of articles regarding mi RNAs occurred in relation to all articles concerning urological neoplasms from 1.06% in 2010 to an estimated 2.63% in 2016. Moreover, ~3.7% of all articles regarding mi RNAs refer to urological neoplasms. This increased research effort, enabled by use of novel method ologies (such as single-cell sequencing approaches or sequencing with increased sensitivity, digital PCR or variations of crosslinking immunoprecipitation methods and state-of-the-art bioinformatics facilities) has distinctly improved our understanding of the molecular processes that occur in urological tumours and also resulted in an increased focus on the translational potential of miRNA research into clinical practice.
MiRNAs have great potential as novel cancer biomarkers [2] [3] [4] [5] [6] . In this Review we provide an update on the use of mi RNAs specifically within the blood and/or urine of patients with urological cancers as diagnostic, prognostic and predictive biomarkers. In particular, we discuss the origin of mi RNAs in biofluids, their use as biomarkers and the qualitative and quantitative changes in mi RNAs in biofluids of patients with bladder, kidney, prostate and testicular cancer.
Biofluid mi RNAs as biomarkers
Molecular processes associated with tumour characteristics, such as tumour stage, grade, size, aggressiveness and metastasis, result in dysregulated miRNA expression profiles in cancer tissue. This dysregulation was reported in The Cancer Genome Atlas (TCGA) studies, which included most urological malignancies [7] [8] [9] [10] [11] . Potentially, these molecular alterations in tumours are mirrored in biofluids, and might be easily detected in blood and urine 12 , providing the rationale for the potential use of mi RNAs as noninvasive cancer biomarkers. According to Fuentes-Arderiu 13 , a biomarker is defined as a "human or animal biological property whose in vitro measurement or identification is useful for the prevention, diagnosis, prognosis, treatment, and follow-up of human or animal diseases, and for their understanding". Finding molecular markers for diagnosis, follow-up monitoring, therapy choice, response prediction and surveillance is of critical importance, especially with regards to personalized medicine 14 . The aim of personalized medicine is to stratify patients into groups with distinct molecular subtypes, which will enable the most suitable therapeutic approach to be selected to prevent unnecessary treatment with severe adverse effects.
MiRNAs can be detected in biofluids as free (or naked) circulating mi RNAs, bound to ribonucleo protein complexes (such as Argonaute proteins, high density lipoproteins or nucleophosmins) or in extracellular vesicles, such as exosomes, microvesicles or apoptotic
The translational potential of microRNAs as biofluid markers of urological tumours Annika Fendler [1] [2] [3] , Carsten Stephan 2, 3 , George M. Yousef 4 , Glen Kristiansen 5 and Klaus Jung 2, 3 Abstract | MicroRNAs (mi RNAs) are secreted by cells in vesicles, bound in a ribonucleoprotein complex or as free molecules. These miRNA secretion pathways are dysregulated in cancer, making mi RNAs attractive candidate molecules for liquid biopsies. A number of studies have investigated the regulation of miRNA secretion into blood and urine and suggested that mi RNAs are noninvasive diagnostic, prognostic and surveillance markers in urological carcinomas, and research in this area has increased over the past 5 years. However, methodological and analytical pitfalls exist and require addressing to enable future translation of the laboratory findings regarding mi RNAs as biomarkers into clinical practice in bladder cancer, kidney cancer, prostate cancer and testicular cancer.
Biofluid mi RNAs in bladder cancer
The low diagnostic sensitivity of cytology for detecting low-grade bladder tumours as well as the inconvenience for patients and the cost of cystoscopy for diagnosis and follow-up monitoring resulted in the development of numerous noninvasive urine-based tests 29 . For example, the FDA has approved the NMP22 test (based on the measurement of the nuclear mitotic apparatus protein 22 (NMP22)), the bladder tumour antigen (BTA) test (based on the detection of the human complement factor H-related protein) and the UroVysion assay (based on a fluorescence in situ hybridization assay for detecting aneuploidy of chromosomes 3, 7, 17 and loss of the 9p21 locus in exfoliated bladder cancer cells). All these commercially available assays have limited clinical validity, mostly owing to their low diagnostic specifi city with the consequence of a high false-positive result rate in benign urinary tract conditions such as infection, inflammation or haematuria 29 . Thus, the dysregulation of mi RNAs in bladder tumour tissue and its possible reflection in urine and in blood have been suggested as promising new biomarkers for bladder cancer 30 . The European Association of Urology (EAU) guidelines on non-muscle-invasive urothelial carcinoma of the bladder define three main purposes in applying new molecular markers for bladder cancer: firstly, screening of the population at risk of developing bladder cancer; secondly, evaluation of patients with symptoms suspicious for bladder cancer; and thirdly, facilitated surveillance of patients with bladder cancer to reduce the number of cystoscopies undertaken 31 . Bladder cancer can be distinguished in to two different types, non-muscle-invasive bladder cancer (NMIBC) is confined to the mucosa or submucosa, in contrast to muscle-invasive bladder cancer (MIBC) that has invaded the muscle. In addition to the diagnosis of cancer, determining recurrence and the risk of progression of NMIBC to MIBC are of clinical interest. For MIBC, events of progression and metastasis (which can change in response to different therapy options) are connected to the clinical end points progression-free survival, cancer-specific survival and overall survival. NMIBC and MIBC differ particularly in their molecular characteristics 32 . A legitimate hope exists that an miRNA pattern dependent on the progressive nature of the bladder cancer 33 could be used as a diagnostic, prognostic and predictive marker through its reflection in biofluids.
MiRNAs in urine samples. In 2010, Hanke et al. 34 published the first report on urinary mi RNAs as diagnostic tools for bladder cancer. Since then, further studies have been published (TABLE 1) . In general, retrospective observational studies in the form of case-control studies have been performed, mostly in single centres. Prospective cohort studies have been the exception. Furthermore, despite the urgent need for markers for surveillance of patients with bladder cancer, few studies investigating mi RNAs in bladder cancer have addressed this issue 52 . The diagnostic capacity of mi RNAs are promising with regards to the global discrimination criterion of an area under the receiver operating characteristics curve bodies [15] [16] [17] [18] [19] (FIG. 2) . Mi RNAs that are bound, complexed or contained in extracellular vesicles are protected from degradation and, as a result, are stable in biofluids 20, 21 . The most extensively studied miRNA-containing vesicles are exosomes. Packaging of mi RNAs into vesicles seems to be selective, as miRNA content in the secreting cells and in vesicles differ from each other 22 . Exosomal secretion of mi RNAs increases in metastatic cancer cells, suggesting they have a specific role in tumour progression 23 . The precise function of secreted vesicles is still under discussion, but results show that mi RNAs enable cells to communicate with each other 6, 18, 19 . Detecting mi RNAs in biofluids is challenging and methodological pitfalls have to be taken into account. Factors that could affect miRNA measurements in the preanalytical, analytical and postanalytical phases of detection include the method of sample collection, processing conditions, storage conditions, RNA isolation technique, quality control, quantification principle and the method of data evaluation [24] [25] [26] [27] [28] 
Furthermore, the development and evaluation of a biomarker assay is a multistage process, including the identi fication of suitable markers in discovery phase, the development of specific, sensitive and robust assays and their validation in various steps
. The development of a marker assay depends on the specific clini cal question and distinct aspects for the respective tumour type must be considered. This process goes well beyond the development of pure diagnostic markers. For example, for prostate cancer, factors such as the identification of suitable markers for the surveillance of patients need consideration, to avoid overtreatment with its risk of adverse effects 5 . All these critical aspects should be considered as the basis for a continuous communication between laboratory scientists, bioinformaticians, clinicians and statisticians in order to ensure reliable data for the clinical decision-making process. These characteristics are a useful starting point for the evaluation of the current status and future challenges regarding using mi RNAs as biomarkers in biofluids.
Key points
• Several hundred micro RNAs (miRNAs) occur in biofluids as free molecules or are secreted in vesicles or bound in a ribonucleoprotein complex • The secretion of mi RNAs into biofluids is dysregulated in cancer making mi RNAs potential noninvasive tumour biomarkers • Studies performed on samples from patients with urological carcinomas suggest that mi RNAs in whole-blood samples, serum, plasma and urine can be applied as novel diagnostic, prognostic and surveillance biomarkers • Inconsistent and contradictory results from studies in bladder, kidney and prostate cancer impede translation of miRNA measurements into routine clinical practice, but a clinically useful signature has been developed for testicular cancer • Preanalytical, analytical and postanalytical differences as well as insufficient power and the heterogeneity of studies are the main factors in shortcomings in this research field • Prospective, multicentre studies that consider all these deficiencies in their design are necessary to assess the real clinical benefit of miRNA measurements in the biofluids of patients with urological carcinomas (AUC) >0.75 (REFS 42, 45, 48, 50, 51) (TABLE 1) . Moreover, some studies reported on the usefulness of mi RNAs as prognostic markers, although no agreement exists regarding the use of specific mi RNAs 41, 51, 52 . The use of miRNA combinations seems to be more advantageous than that of single mi RNAs 42, 43, 52, 54 . However, the lack of external validation of all mi RNAs proposed as biomarkers prevents general conclusions on the clinical utility of mi RNAs as biomarkers at present. In addition, factors such as differing study designs (in the relation to the objective of the study and the clinical heterogeneity of study cohorts -patients with MIBC or NMIBC were included) and use of different urine test materials for miRNA measurements -urinary mi RNAs were determined in native, noncentrifuged urine, in sediment, in urine supernatant after first standard centrifugation and in extracellular vesicles like exosomes -make comparison difficult. In addition, the processing conditions for the preparation of test material were often not clearly reported. No consensus exists on what type of sample should be used, although test kits are commercially available for all these sample materials (from companies such as Norgen, Qiagen and Exiqon) 45 . Furthermore, the choice of which mi RNAs to detect differed between each study. For example, in some studies mi RNAs were selected for measurement in urine samples in relation to their differential expression in tumour tissue identified in external or investigators' own previous studies. This approach might not result in the detection of the most suitable biomarkers. MiRNA secretion is a highly regulated process and the composition of mi RNAs in biofluids and cells can differ greatly. Other investigators decided on the panel of mi RNAs according to the detection of released mi RNAs in conditioned cell culture medium, despite the fact that cell lines frequently differ in their molecular characteristics in comparison to the primary tumour cells. Genome-wide discovery experiments in a first study phase, using sequencing or array technologies, and subsequent validations with individual reverse-transcription quantitative (RT-q)PCR for each miRNA in the biofluid of interest are more meaningful and comprehensive methods of biomarker detection 50, 54, 59 . Importantly, in most studies, the evaluation of the diagnostic validity of mi RNAs was limited without consideration of the recommendations included in the EAU guidelines. Generally, direct comparison of the performance of mi RNAs with conventional cytology or other urine tests was not performed, with the exception of studies by Sapre et al. 52 and Eissa and colleagues 48 . Sapre et al. 52 calculated that their recommended miRNA monitoring set (diagnostic sensitivity 88%, diagnostic specificity 48% and negative predictive value 75%) could reduce the cystoscopy rate by 30%. Eissa et al. 48 used an integrative approach combining cytology results with data regarding the expression of two mi RNAs (miR-96 and miR-210) and the long noncoding RNA urothelial cancer associated 1 (UCA1) and achieved remarkable discrimination between patients with bladder cancer and those with negative cystoscopy results with an AUC value of 0.933. Thus, in contrast to these two examples, Nature Reviews | Urology 31 . Thus, mi RNAs occurring in erythrocytes must be excluded as biomarkers for bladder cancer 61, 63 . However, several studies have investigated mi RNAs that are obviously affected by haemolysis with regards to their levels, apparently without consideration of the potential for interference (TABLE 1) . Thus, numerous mi RNAs that have been suggested to be cancer-specific biomarkers in various studies are likely to reflect haematuria but not the dysregulation of mi RNAs in bladder cancer tissue.
MiRNAs in serum and plasma samples. Current data and understanding regarding mi RNAs in blood are simi lar to those regarding mi RNAs in urine. To date, eight studies concerning miRNA levels in serum or plasma have been reported (TABLE 1) . Published in 2013, the first studies in this field measured selected mi RNAs that had previously been found to be dysregulated in bladder cancer tissue. However, data from two studies published in 2015 (REFS 54, 59) , used a genome-wide, array-based profiling discovery phase with subsequent validation phases and corresponding large training and validation cohorts. Their results can be robustly assessed concerning the diagnostic and prognostic potential of circulating mi RNAs (TABLE 1) . Du et al. 59 achieved a global discrimination between control participants and patients with bladder cancer with an AUC value of 0.711 using a combination of miR-497 and miR-663b expression levels, which were selected from eight differentially expressed mi RNAs that had been identified in the discovery phase. These data were obtained using a two-phase validation method with separate training and validation cohorts. Jiang et al. 54 applied a similar approach; however, based on sequencing data of pooled serum samples in a discovery phase, a robust panel of six mi RNAs was identified in a training phase including 120 patients and 120 controls and 
Biofluid mi RNAs in kidney cancer
The clinical management of patients with renal cell carcinoma (RCC) is mainly based on traditional clinicopathological and radiological examination. However, the diagnostic, prognostic and predictive models that are based on these conventional data alone have limited accuracy and need improving 64 . In contrast to other cancer types, robust, noninvasive blood or urine biomarkers for all histological RCC subtypes are still lacking. Owing to these issues, the discovered effect of mi RNAs on the initiation and progression of RCC has fuelled the desire to translate these new insights into novel miRNA-based biomarkers in biological fluids, such as blood and urine.
MiRNAs in serum, plasma and urine samples. Available studies concerning mi RNAs as biomarkers for RCC have striking particularities in their designs, preanalytical conditions and analytical conditions [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] (TABLE 2) .
Specifically, relatively few studies, including only one multicentre study 67 , have been conducted, and most investigators did not perform an internal validation with a training and validation set or even include an internal validation approach, such as bootstrapping or crossvalidation. Moreover, all studies except one used serum as the source of RNA despite plasma being the blood component of choice, as the release of mi RNAs from blood cells such as miRNA-enriched platelets into serum occurs during the coagulation process 77 . Furthermore, collection processing was often incompletely described, and only one study 73 controlled for the effect of haemolysis as an interfering factor in miRNA measurement. In addition, different strategies were applied for normalizing RT-qPCR data and contrasting results regarding the regulation of miR-378, for example, were reported in three studies 68, 72, 74 . All studies conducted to date have primarily focused on the diagnostic objective of discrimination between patients with RCC and healthy control subjects. The study cohorts consisted either of patients with only clear cell RCC (ccRCC) [69] [70] [71] 74 -the subtype with the highest incidence -or patients with papillary, chromophobe or sarcomatoid RCC 67, 68, 72, 75 . To date, no studies have been performed that investigate the clinical need for differentiating histological RCC subtypes using biofluid samples. Discrimination of RCC subtypes using mi RNAs has already been achieved successfully using tissue samples and is important for the risk stratification of patients 78 . The use of more than one miRNA is generally recommended to obtain improved accuracy and robustness of results 72, 74 . Some studies compared circulating miRNA data with the simultan eously acquired miRNA profiling data of matched RCC and normal tissue 67, 69, 71 . The observed changes in circulating mi RNAs were not always concordant with the tissue expression levels 67, 79 and association with clinicopathological factors such as tumour stage and grade were not observed 69, 71, 72, 75 . Such differences should not generally be interpreted as a contradiction; such distortions between cellular and circulating markers are possible as the molecular releasing processes of the different mi RNAs from cells into the extracellular • Eight patients
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• 51 patients • 24 subjects with negative cystoscopy results Urine sediment and supernatant
• miR-200 family • Discovery: Exiqon array • Osmolarity adjusted 
• Diagnosis of cancer with all mi RNAs (AUC = 0.899, DS = 80%, DSp = 89%) differentiation of NIMBC from MIBC (AUC = 0.841, DS = 90%, DSp: 66.4%) • Prognostic marker set miR-152
and miR-3187-3p: recurrence-free survival for NIMBC, not for MIBC (TABLE 2) . However, the necessity of validating these results in independent validation cohorts became evident in a multicentre study 67 . MiR-1233 was the only miRNA out of seven potential candidates selected after discovery and verification phases that maintained different expression values between patients and control subjects in a validation phase. It had an AUC value of only 0.588 (95%CI 0.505-0.671) for independent study cohorts, which is lower than the AUCs that had been reported in studies without independent study cohorts 68, 70, 71 . In two studies, a decline in the concentration of miR-210 and miR-378 was observed after nephrectomy for treatment of RCC 70, 72 , and both mi RNAs were suggested as potential indicators of cancer recurrence in follow-up monitoring of patients with RCC. Only one study demonstrated that miRNA expression could function as an independent prognostic marker, in which an increased expression level of miR-221 was associated with poor overall survival 75 . The predictive ability of a multivariate model that included tumour stage, Fuhrman grade and age ≥60 years was improved if the circulating miR-221 expression level was also included, demonstrated by the increase of the hazard ratio from 4.7 without miR-221 expression to 10.7 with expression included 75 . However, another study investigating the diagnostic and prognostic utility of miR-221 and miR-378 did not verify this predictive ability 72 . Thus, the evaluation of the potential of mi RNAs as tools for risk stratification remains an important research goal.
Gamez-Pozo et al. 76 performed a particularly interesting study with regard to the use of miRNA signatures for personalizing treatment for metastatic RCC. The investigators examined the miRNA profiles of leucocytes in peripheral blood samples from patients receiving sunitinib for advanced RCC using microarrays. RT-qPCR-validated predictive models were developed using differentially expressed mi RNAs identified in a microarray analysis to distinguish patients with cancer likely to be resistant to sunitinib before the treatment was started; these models were also informative with regards to overall survival. This promising approach, published in 2012, has yet to be verified in an independent study. Wholeblood (PAXgene) Surprisingly, only one study using urine samples for miRNA analyses in patients with RCC has been reported. Von Brandenstein et al. 65 measured miR-15a levels in whole-urine samples from patients with ccRCC. Distinctly higher concentrations were observed in patients with ccRCC than in the urine of patients with benign renal oncocytoma, urinary bladder cancer or other, nonurological tumours. This increase was probably caused by an active release of mi RNAs from the tumour cells in exosomes. After nephrectomy, the concentration of miR-15a decreased to nearly zero by the time of hospital discharge. Thus, careful assessment of the potential of mi RNAs in urine and its fractions as diagnostic and prognostic markers for RCC is urgently required.
MiRNAs as biomarkers in kidney cancer. In summary, despite some promising data no immediate prospect exists that mi RNAs will be introduced as diagnostic or prognostic biomarkers either alone or in combination with the traditional clinicopathological factors in the routine management of patients with RCC. The lack of translational potential of mi RNAs as biofluid biomarkers in RCC is probably a result of insufficient consideration of preanalytical and analytical variables, study heterogeneity and the retrospective nature of the reported studies. Also, studies using reference and target mi RNAs that could be affected by haemolysis (such as miR-16, miR-21, miR-210 and miR-451) 61, 63 are possibly biased. Prospective studies are necessary and should consider all variables that could influence the detection of mi RNAs in biofluids
.
Biofluid mi RNAs in prostate cancer
The use of serum PSA concentration as a screening marker for prostate cancer has resulted in controversial recommendations and debates 81 . One key point regarding the critical assessment of this marker is its limited ability to discriminate between aggressive tumours that need treatment and clinically insignificant tumours or benign prostatic diseases that do not require intervention but should undergo active surveillance 81 . Consequently, current biomarker research is focused on the translation of the new insights into molecular alterations in prostate cancer 82 into noninvasive biomarkers, including mi RNAs, in biofluids that would not have the disadvantages of PSA. Other purposes are the development of monitoring assays that reflect response to hormonal therapies, chemotherapeutic or radiotherapeutic options for prostate cancer treatment or improve prognostic information for both clinicians and patients 3, 5 .
MiRNAs in blood, serum and plasma samples. In 2008, Mitchell et al. 20 presented the first data showing differing circulating miRNA concentrations in the serum of patients with metastatic prostate cancer in comparison with matched healthy controls. These findings triggered a storm of enthusiasm and resulted in a wave of subsequent studies and numerous reviews. To date, 37 reports investigating mi RNAs in whole-blood samples, serum, plasma, peripheral mononuclear cells and exosomes have been published. Also, 10 articles have been published regarding urinary mi RNAs in samples from patients with prostate cancer 20, (TABLE 3) .
The starting points of these studies for the identification of useful mi RNAs (such as a profiling discovery phase, dysregulated tumour tissue expression data, cell culture results or data in the literature) and the subsequent validation phase were different, as has been observed for studies regarding miRNA expression in other urological tumours. This disparity and the heterogeneity and size differences of study cohorts make a comparison of the data between studies difficult. However, an assessment of the numerous studies with regards to the translation of miRNA biomarker research into clinical practice is facilitated by taking into account assessment criteria
. This comparison is possible by comparing results regarding the same mi RNAs measured in different studies with broadly similar objectives. The most frequently investigated mi RNAs were miR-141 (in 15 studies), miR-21 (in 10 studies), miR-375 (in eight studies) and miR-221 (in seven studies). For example, the usefulness of miR-141 as marker for early detection of prostate cancer was only found in two out of six corresponding diagnostic studies 121, 126 . In nine out of the 15 miR-141-studies, miR-141 was only evaluated as a marker of advanced or meta static prostate cancer 20, 84, 96, 99, 101, 103, [113] [114] [115] (TABLE 3) , but (in studies in which a comparison was made) was frequently, not better than the routine marker PSA 114, 115, 118 . These data underline the fact that the clinical relevance of a marker can only be truly assessed if studies with similar questions are compared: a useful diagnostic marker might be a useless prognostic marker and vice versa. Similarly, miR-21 proved to be unsuitable as an early marker in four studies 88 Whole-urine after DRE
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• 38 patients with prostate cancer before and after radical prostatectomy • 40 healthy controls
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Prediction of risk groups: all mi RNAs were different between the risk groups; miR-187, miR-188-5p, miR-196b together with clinical variables were the best predictors of risk groups; detailed data were not given 123 . MiR-375 seems to be a specifically useful marker for prostate cancer. Two studies showed that use of miR-375 expression levels provided better discrimination between patients with prostate cancer and control subjects than PSA 113, 120 . MiR-375 was also reported as a marker for metastatic prostate cancer 96, 118 and a prognostic marker for overall survival 124 . However, two other studies did not find that this miRNA could be used as tool to discriminate between patients with a positive biopsy result and those with a negative result or between patients stratified as having low-risk or high-risk prostate cancer 88, 121 . These examples illustrate that results regarding the utility of specific mi RNAs as biomarkers can be discrepant between various studies. These differences can be caused by differences in sample material and the study objective. Results published since 2015 120, 121, (123) (124) (125) (126) (TABLE 3) report more promising diagnostic and prognostic data than earlier studies. One reason for this improvement could be that combinations of different mi RNAs 111, 121 , mi RNAs in combination with other markers 113, 120 and mi RNAs in blood cells 123 or exosomes 124 were investi gated, rather than single mi RNAs. However, the promising results of these studies are yet to be validated.
MiRNAs in urine samples. In 2012, the FDA approved the Progensa PCA3 test that determines the ratio of PSA mRNA to the long noncoding RNA PCA3 in urine after standardized digital manipulation of the prostate for use in the decision-making process for repeat biopsy. Since then, several studies have been published that investigate the use of mi RNAs in urine as predictive markers for positive biopsy results or the presence of high-risk cancer. However, results are divergent [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] (TABLE 3) and no firm conclusions can be made regarding the utility of mi RNAs in urine as biomarkers for prostate cancer.
MiRNAs as biomarkers in prostate cancer. Whether the determination of miRNA in blood, serum, plasma and/or urine of patients with prostate cancer could be a useful clinical tool remains an open question. The evalu ation of the various studies according to the criteria for the development of a biomarker assay (BOX 2) need to be considered. Specifically, the selection of mi RNAs that are not affected by haemolysis is not only necessary for the determination of mi RNAs in serum and plasma samples but also, in particular, in urine samples; generally, the urine-based studies did not consider that urine samples after digital rectal examination (DRE) might become dipstick-positive for haematuria, as has been observed in 30-40% of samples, depending on the examiner (K. Jung, unpublished work). However, several studies used haemolysis-affected mi RNAs as their markers (TABLE 3) and these study results are probably biased. Moreover, different urine preparations (such as whole urine, sediment or supernatant after centri fugation either after DRE or without DRE) were used. In this situation, contamination of miRNA levels is possible from unspecific bladder cells that interfere with the detected concentration of mi RNAs released after DRE from prostate tumour cells as exosomal and protein-bound mi RNAs or mi RNAs in cells shed from the tumour 92 . Moreover, most studies investigating the diagnostic and/or prognostic utility of miRNA biomarkers did not consider STARD or Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) guidelines 62, 127 . These guidelines require that results of the comparator test (the reference standard) for the diagnostic objective and results in relation to the standard prognostic variables for predicting clinical end points should always be reported in addition to the results regarding the biomarker assay examined. Several studies were not appropriately designed for answering the question of whether miRNA biomarkers enable incremental information beyond the conventional standards for predicting biopsy outcome or disease progression. This inadequacy is evident in urinary and blood miRNA studies as PCA3 in urine and the best serum PSA derivative, the Prostate Health Index, were rarely used as comparator tests 86, 92 . Studies that applied multivariate Cox regression analysis for the assessment of clinical usefulness of miRNA concentrations as independent markers for predicting biochemical recurrence after prostatectomy or other outcomes are currently the exceptions 104, 111, 124 .
Biofluid microRNAs in testicular cancer
In 2010, the overexpression of the miRNA clusters miR-371-373 and miR-302-367 in all testicular cancers and their association with stem cells, as previously described 128, 129 , was reaffirmed 130 . Subsequently, the expression levels of these tissue-based signatures were measured in serum [131] [132] [133] [134] [135] [136] . These liquid biopsy data confirmed the potential utility of miRNA measurements for discriminating patients with seminoma or those with nonseminoma from healthy controls. A selected set of four mi RNAs (miR-371a-3p, miR-372, miR-373 and miR-367) present in the two clusters that showed the highest discriminative power for diagnosis and follow-up monitoring of cancer, combined with reference mi RNAs (miR-20a and miR-93) and spike-in controls was developed as the 'targeted serum miRNA assay' (TSmiR) 136 . This test showed a distinctly higher diagnostic sensitivity of 98% in a cohort of 80 patients with testicular cancer and 47 controls from five different groups than the standard markers α-fetoprotein and β-human chorionic gonadotropin, which had sensi tivities of only 36% and 57%, respectively. In addition, serum levels of these four mi RNAs normalized after orchiectomy and decreased after chemotherapy in patients with metastatic disease, and miR-371a-3p was the most sensitive marker for detecting these changes 134, 136 . Two independent studies, confirmed these promising results for miR-371a-3p as a biomarker for testicular cancer; however these reports only included a limited number of participants 132, 133 . A simplified assay for analysing miR-371a-3p without endogenous controls was recommended to reduce laboratory work, analytical time and costs 137 . Results of another study confirmed the discriminative ability of serum miR-371a-3p and miR-372 concentrations and also identified numerous novel discriminative serum mi RNAs (miR-511, miR-26b, miR-769, miR-23a, miR-106b, miR-365, miR-598, miR-340 and let-7a), which were identified using a high-throughput profiling system, but did not validate the results 131 . Ruf et al. 138 evaluated next-generation sequencing miRNA data obtained from RNA isolated from whole-blood samples from patients with seminoma using support vector machines as classifier method with different combinations of two mi RNAs to discriminate between metastasized and nonmetastasized cancer. Their approach combined simplification of sample collection with sophisticated technology and data analysis, which are important landmarks for translational research. Overall, 33-35 mi RNAs with differential expression were identified and complete discrimination of patients with metastasized seminoma from those with nonmetastasized seminoma was achieved using numerous combinations of pairs of these mi RNAs, for example miR-18a and miR-532, miR-19b-1 and miR-342 or miR-28 and miR-574.
MiRNAs as biomarkers in testicular cancer. In summary, the current data considered together and despite the limited sample sizes in the individual studies provide convincing evidence for the use of mi RNAs as biomarkers for testicular cancer. Supported by further positive data from an ongoing prospective multicentre study by the German Testicular Cancer Group (AUO No. AH 14/15-MicroRNA from the German Association of Urogenital Oncology), the introduction of miRNA measurements is anticipated for the clinical management of patients with testicular germ cell tumours in the near future.
Future perspectives
The number of studies investigating circulating mi RNAs in urological tumours has increased greatly in the past 5 years; next-generation sequencing has also become faster and more affordable enabling rapid systematic sequencing of samples in large-scale, multicentre studies, facilitating biomarker research. Current studies confirm that noninvasive measurement of circulating miRNA concentrations in urological carcinomas is possible and that dysregulation of mi RNAs is specific for patients with cancer. A number of study results show that the expression changes that have been described in tissue are not always reflected in blood or urine, highlighting that regulated secretion pathways exist. Systematic multicentre studies, addressing the specific miRNA expression patterns (as have been performed in tissue samples) are missing in biofluids. Without these unbiased screening studies, some potential markers might still be undiscovered. The comparability and translational potential of the current studies is limited, even though the number of studies is increasing. The reasons for these discrepancies are the existing preanalytical and analytical differences and the heterogeneity of tested specimens. No consensus exists regarding which miRNA isolation method is most suitable for miRNA detection in serum, plasma or urine samples, and different preparations of blood (such as plasma, serum or whole blood) or urine (such as whole urine, supernatant or sediment taken after or without DRE) have been used. Other important analytical factors include haematuria and haemolysis. Follow-up studies must stringently control miRNA expression to mitigate the effects of haemolysis in order to exclude false-positive results. Analytical issues such as sensitivity, specificity, accuracy and robustness of the detection assays have not been sufficiently studied and need to be addressed. Next-generation sequencing and digital PCR might prove to be more accurate and sensitive than conventional miRNA expression profiling by microarray and RT-qPCR. A comparison of miRNA sequencing, microarray or RT-qPCR profiling has indicated that each method has specific weaknesses, highlighting that which method to use must be considered with regards to the specific study design and end point 139 .
Validation of miRNA expression in independent cohorts and multicentre studies is limited. Additional prospective, multicentre studies, which stringently control preanalytical and analytical conditions, are necessary. In these studies, the end points should be clearly defined and should address the specific clinical needs, such as surveillance markers in bladder cancer to reduce the need of invasive cystoscopy, stratification of aggressive prostate tumours or predictive markers in kidney cancer, which are important clinical issues that have not been sufficiently addressed. These studies would also enable the inclusion of miRNA markers into multivariate models. The resulting models should be compared with current standard markers. Without the existence of these studies, conclusive results on single mi RNAs or miRNA combinations as diagnostic, prognostic or predictive markers is not possible.
Conclusions
Circulating mi RNAs are promising marker candidates for urological tumours. In testicular cancer particularly, a number of studies have good overlap with regard to the specific miRNA markers enabling comparison of the data and speedy translation of mi RNAs as diagnostic markers into clinical practice. In bladder, kidney and prostate cancer, further studies are needed to address the methodological differences and large prospective studies concerning the respective clinical questions should be initiated to discover the usefulness of mi RNAs as biomarkers in biofluids.
